The Central Hospital of Huanggang
10
5
5
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 10 trials
100.0%
+13.5% vs industry average
10%
1 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Monitoring of Antimicrobial Resistance Based on Metagenomics Analyses in Pneumonia Patients
Role: collaborator
Tirofiban After Successful MT Recanalization in AIS
Role: collaborator
Efficacy and Safety of Early Combined Therapy With PCSK9 Inhibitors and Statins in Acute Ischemic Stroke
Role: collaborator
Impact of Pre-Hospital Heparin Loading in STEMI Patients for Primary PCI: The HELP-PCI 2 Trial
Role: collaborator
The Impact of Transjugular Intrahepatic Portosystemic Shunt on Recompensation in Patients With Decompensated Liver Cirrhosis
Role: collaborator
Total Infectome Characterization of Eye Infections
Role: collaborator
Early Administration of Heparin At FMC for PPCI of STEMI Patients
Role: collaborator
SPT-07A Injection in Patients With Acute Ischemic Stroke (AIS): A Phase III Clinical Trial
Role: collaborator
Comparing the Safety and Effectiveness of Tunnel PICC Guided by EDUG and Conventional PICC
Role: collaborator
The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer
Role: collaborator
All 10 trials loaded